Partnership powering novel cancer therapies
Verastem Oncology (verastem.com) scores 83 out of 100 on Brand Analyzer, placing it in the Strong Brand tier among Healthcare brands, in the 84th percentile of 9451 Healthcare brands.
Verastem Oncology is a Massachusetts-based pharmaceutical company founded in 2010 that develops precision therapies for cancers driven by mutations in the RAS/MAPK signaling pathway. It is known for developing the first FDA-approved therapy for KRAS-mutant recurrent low-grade serous ovarian cancer. The company emphasizes collaborative research partnerships to address unmet needs in rare and prevalent cancer mutations, targeting oncologists, patients, and the broader medical research community. Robert Forrester serves as CEO.
| Brand Name | Verastem Oncology |
|---|---|
| Domain | verastem.com |
| Industry | Healthcare |
| Founded | 2010 |
| Headquarters | Needham |
| CEO | Robert Forrester |
| Main Competitors | Amgen (90/100), Revolution Medicines (82/100), Mirati Therapeutics, Exelixis, Erasca, Boehringer Ingelheim (76/100) |
Moz Domain Authority 41/100 vs category average 41 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
Ranked #1,138,003 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
Verastem Oncology has a dedicated Wikipedia entity - a top-weighted signal AI models rely on to identify and describe the brand.
The homepage meta description reads "Embracing the power of partnership and collaboration to develop novel cancer therapies." (Meta description: 12 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 1 JSON-LD block(s), Organization schema, og:title, og:description, og:image, og:type, Twitter cards, canonical. Adding FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Cloudflare, WordPress, Ghost.
Social footprint: verified profiles on X (Twitter), LinkedIn, Facebook, Instagram; no detected presence on YouTube, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked September 2026.
When asked "What is Verastem Oncology?", Claude could identify the brand as of September 2026. Verastem Oncology is a biopharmaceutical company focused on developing and commercializing medicines for patients with cancer, particularly targeting RAS/MAPK pathway-driven cancers. Its key product is avutometinib, often studied in combination with defactinib, for indications li Best known for Developing avutometinib plus defactinib combination therapy for RAS/MAPK pathway-driven cancers, including low-grade serous ovarian cancer.
When asked "Best brands similar to Verastem Oncology?", Claude would recommend Verastem Oncology as of September 2026. It's a notable clinical-stage oncology company with a differentiated RAS/MAPK pathway approach, so it would come up in discussions of targeted cancer therapy developers.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Verastem Oncology's main competitors in Healthcare: Amgen (90/100), Revolution Medicines (82/100), Boehringer Ingelheim (76/100).
Sources: Brand Analyzer scan
Verastem Oncology is a pharmaceutical company headquartered in Needham, Massachusetts, founded in 2010. It focuses on developing precision medicines for cancers driven by mutations in the RAS/MAPK signaling pathway, a common driver of many solid tumors. The company is led by CEO Robert Forrester and operates within the healthcare and biopharmaceutical sector.
Sources: Verastem Oncology official site
Verastem Oncology has moderate AI-search visibility, scoring 53/100 on Brand Analyzer's AI visibility composite (visibility 63, trust 36, recommendation 57). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Verastem Oncology official site
Verastem Oncology was founded in 2010. Verastem Oncology operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
Verastem Oncology is headquartered in Needham. Verastem Oncology operates in the Healthcare category.
Sources: Wikidata
Verastem Oncology researches, develops, and delivers novel therapies targeting RAS/MAPK pathway-driven cancers. The company works to bring precision treatments to patients with rare and prevalent cancer mutations, including KRAS-mutant tumors, through collaborative partnerships in drug development and clinical research.
Sources: Verastem Oncology official site
Verastem Oncology scores 57/100 on Brand Analyzer's AI recommendation signal, indicating it is reasonably likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority; a Wikipedia presence helps.
Sources: Verastem Oncology official site
Verastem Oncology develops precision cancer therapies targeting RAS/MAPK pathway-driven cancers. Its portfolio includes an FDA-approved treatment for KRAS-mutant recurrent low-grade serous ovarian cancer, along with ongoing research and development programs targeting other RAS/MAPK pathway-driven cancers, including KRAS-mutant solid tumors.
Sources: Verastem Oncology official site
Verastem Oncology is known for developing the first FDA-approved therapy for KRAS-mutant recurrent low-grade serous ovarian cancer, positioning it as a pioneer in precision oncology for RAS/MAPK pathway-driven cancers, a category with historically limited treatment options.
Sources: Verastem Oncology official site
Verastem Oncology can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Verastem Oncology official site
Verastem Oncology's therapies and research are used by oncologists treating patients with RAS/MAPK pathway-driven cancers, particularly those with low-grade serous ovarian cancer and KRAS-mutant solid tumors. The company also engages the broader medical and research community focused on precision oncology and targeted cancer treatments.
Sources: Verastem Oncology official site
Verastem Oncology has gained recognition in the oncology field for developing the first FDA-approved therapy specifically for KRAS-mutant recurrent low-grade serous ovarian cancer, addressing a critical unmet medical need. Its focus on RAS/MAPK pathway-driven cancers, an area of significant scientific interest due to the prevalence of these mutations across various solid tumors, has positioned it as a notable player in precision oncology research and development.
Sources: Verastem Oncology official site
Verastem Oncology scores 53/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Verastem Oncology has a limited AI-visibility profile at 53/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is visibility (63/100) and its weakest is trust (36/100). It benefits from a recognised Wikipedia company entity, a Wikidata knowledge-graph entry and a global traffic rank of #1,138,003 (Tranco). The main gaps holding it back: no llms.txt to steer AI to its best pages. In a live check, Claude could already identify Verastem Oncology from memory (September 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Verastem Oncology: Veracyte (83/100), VCA Animal Hospitals (83/100), Verisys (83/100), Vets Now (83/100).
A step up - brands to learn from: Zoetis (91/100), theSkimm (91/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.